{"created":"2023-06-20T15:46:10.418067+00:00","id":761,"links":{},"metadata":{"_buckets":{"deposit":"6cbe7ab1-2e58-4837-85ed-6669622b5c51"},"_deposit":{"created_by":4,"id":"761","owners":[4],"pid":{"revision_id":0,"type":"depid","value":"761"},"status":"published"},"_oai":{"id":"oai:uoeh-u.repo.nii.ac.jp:00000761","sets":["13:23:37"]},"author_link":["2646","2638","2635","2641","2639","2643","2642","2647","2640","2644","2637","2634","2645","2636"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2017-03-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"9","bibliographicPageStart":"1","bibliographicVolumeNumber":"39","bibliographic_titles":[{"bibliographic_title":"産業医科大学雑誌"},{"bibliographic_title":"Journal of UOEH","bibliographic_titleLang":"en"}]}]},"item_10001_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"We analyzed the effects of 100 mg/day sitagliptin and a switch to mitiglinide calcium hydrate/voglibose compound tablets (MIT/VOG) in patients with type 2 diabetes mellitus (T2DM) treated with 50 mg/day sitagliptin. Five patients with T2DM treated with 50 mg/day sitagliptin and hemoglobin A1c (HbA1c) of ≥6.5% were switched to MIT/VOG, or the dose of sitagliptin was increased to 100 mg/day. The effects of the changes in therapy were compared in a crossover fashion by continuous glucose monitoring. The primary endpoint was mean amplitude of glycemic excursions (MAGE), and the secondary end points were 24-hour mean blood glucose level and mean blood glucose level from 0:00 a.m. to 7:00 a.m. and from 7:00 a.m. to 0:00 a.m., percentage of time with blood glucose level of ≥200 mg/dl and <70 mg/dl, maximum and minimum blood glucose levels, and increases in postprandial blood glucose levels. MAGE was significantly lower with MIT/VOG (P = 0.016), whereas mean blood glucose levels were lower between 0:00 a.m. and 7:00 a.m. with 100 mg/day sitagliptin. The percentage of time with blood glucose level ≥200 mg/dl was significantly shorter with MIT/VOG (P = 0.041). The maximum blood glucose level was significantly lower with MIT/VOG (P = 0.043), and the minimum was significantly lower with 100 mg/day sitagliptin (P = 0.043). Blood glucose levels after dinner and mean increases in postprandial blood glucose levels were significantly lower with MIT/VOG (P = 0.090 and P = 0.045 respectively). In patients with T2DM, treatment with MIT/VOG improves MAGE andpostprandial hyperglycemia and 100 mg/day sitagliptin lowers early morning glucose levels. This trial was registered with the University Hospital Medical Information Network (UMIN) (No. UMIN R000008274).","subitem_description_type":"Abstract"},{"subitem_description":"シタグリプチン（sitagliptin; S）50 mgで効果不十分な2型糖尿病患者をS 100 mgに増量する群とミチグリニドカルシウム水和物・ボグリボース（mitiglinide calcium hydrate / voglibose）配合錠（M/V）に変更する群とに分け，両薬剤の特徴や差異を明らかにする．S 50 mgにて加療中のHbA1c 6.5% 以上の2型糖尿病患者5名にM/V に切替群，S 100 mg増量群に無作為に割り付け，5日間投与後にクロスオーバーを行う．主要評価項目は，平均血糖変動幅（MAGE），副次評価項目は24時間平均血糖，血糖200 mg/dl 以上，70 mg/dl 未満出現頻度，午前0時～午前7時平均血糖，午前7時～午前0時平均血糖，最大血糖，最小血糖，各食前血糖，食後血糖上昇幅とした．MAGE は，M/VでP =0.016と有意に低かった．24時間平均血糖，午前0時～午前7時平均血糖，午前7時～午前0時平均血糖に差は無かったが，午前0時～午前7時平均血糖はS 100 mgで低い傾向が見られた．血糖70 mg/dl 未満はなく，血糖200 mg/dl以上の時間はM/VでP = 0.041と有意に短かった．最大血糖はM/VでP = 0.043と有意に低く，最小血糖はS 100 mgでP =0.043と有意に低かった．朝食後，昼食後血糖上昇幅に差はないが，夕食後と平均の食後血糖上昇幅はM/Vで各々P= 0.090，0.045 と有意に低かった．2 型糖尿病患者では，M/V への変更で平均血糖変動幅や食後高血糖が改善し，S 100 mgへの増量では深夜から早朝の血糖が低下する特徴が明らかになった．この研究は，大学病院医療情報ネットワーク（UMIN）に登録された（No.UMIN R000008274）．","subitem_description_type":"Abstract"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"産業医科大学（産業医科大学学会）"}]},"item_10001_relation_17":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"Journal of UOEH"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://www.jstage.jst.go.jp/browse/juoeh/39/1/_contents/-char/ja","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"産業医科大学雑誌"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://www.uoeh-u.ac.jp/kouza/journal/i_2017-1j.html","subitem_relation_type_select":"URI"}}]},"item_10001_select_24":{"attribute_name":"記事区分","attribute_value_mlt":[{"subitem_select_item":"Original"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"ISSN 0387-821X(PRINT), ISSN 2187-2864(ONLINE)","subitem_source_identifier_type":"ISSN"}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"新生, 忠司"}],"nameIdentifiers":[{"nameIdentifier":"2634","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"岡田, 洋右"}],"nameIdentifiers":[{"nameIdentifier":"2635","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"鳥本, 桂一"}],"nameIdentifiers":[{"nameIdentifier":"2636","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"須貝, 慧"}],"nameIdentifiers":[{"nameIdentifier":"2637","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"大塚, 隆史"}],"nameIdentifiers":[{"nameIdentifier":"2638","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"黒住, 旭"}],"nameIdentifiers":[{"nameIdentifier":"2639","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"田中, 良哉"}],"nameIdentifiers":[{"nameIdentifier":"2640","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Arao, Tadashi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2641","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Okada, Yosuke","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2642","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Torimoto, Keiichi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2643","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sugai, Kei","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2644","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Otsuka, Takashi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2645","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kurozumi, Akira","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2646","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tanaka, Yoshiya","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2647","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-03-18"}],"displaytype":"detail","filename":"S00039101.pdf","filesize":[{"value":"879.0 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"S00039101.pdf","url":"https://uoeh-u.repo.nii.ac.jp/record/761/files/S00039101.pdf"},"version_id":"d275e5fb-9f82-47e1-b03c-86b13a67b6f3"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"2型糖尿病","subitem_subject_scheme":"Other"},{"subitem_subject":"シタグリプチン","subitem_subject_scheme":"Other"},{"subitem_subject":"ミチグリニドカルシウム水和物・ボグリボース","subitem_subject_scheme":"Other"},{"subitem_subject":"持続的グルコースモニタリングシステム","subitem_subject_scheme":"Other"},{"subitem_subject":"平均血糖変動幅","subitem_subject_scheme":"Other"},{"subitem_subject":"type 2 diabetes mellitus","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"sitagliptin","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"mitiglinide calcium hydrate/voglibose","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"continuous glucose monitoring system","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"mean amplitude of glycemic excursions","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"2 型糖尿病患者におけるシタグリプチン50 mgから100 mgへの増量とミチグリニドカルシウム水和物・ボグリボースへの切り替えにおける有用性に関する比較検討","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"2 型糖尿病患者におけるシタグリプチン50 mgから100 mgへの増量とミチグリニドカルシウム水和物・ボグリボースへの切り替えにおける有用性に関する比較検討"},{"subitem_title":"Comparison Between Effectiveness of 100 mg/day Sitagliptin and a Switch to Mitiglinide Calcium Hydrate/Voglibose from 50 mg/day Sitagliptin in Patients with Type 2 Diabetes","subitem_title_language":"en"}]},"item_type_id":"10001","owner":"4","path":["37"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-08-03"},"publish_date":"2020-08-03","publish_status":"0","recid":"761","relation_version_is_last":true,"title":["2 型糖尿病患者におけるシタグリプチン50 mgから100 mgへの増量とミチグリニドカルシウム水和物・ボグリボースへの切り替えにおける有用性に関する比較検討"],"weko_creator_id":"4","weko_shared_id":-1},"updated":"2023-06-20T15:58:14.487758+00:00"}